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The burden of malaria
In South Africa, malaria is endemic in three provinces – Limpopo, 
Mpumalanga and KwaZulu-Natal (Fig. 1) – and transmission occurs 
predominantly between September and May.1 Over the past decade, 
the National Department of Health (DoH) has focused intense efforts 
on preventing the local transmission of malaria, and on ensuring the 
prompt and effective management of cases, especially in the endemic 
provinces. The DoH has recorded significant success in reducing the 
burden of malaria through the implementation of its key interventions: 
Vector Control, Case Management, Surveillance, Health Promotion, 
and Epidemic Preparedness and Response. Notified malaria cases in the 
aforementioned provinces have decreased by 88% over the past decade, 
from 64 622 cases in 2000 to 7 626 in 2010. In the same period, malaria-
related deaths have been reduced by 81%, from 458 to 87 deaths.2 
Malaria has been a notifiable disease in South Africa since 1956 
(Government notice No. 2 081 of 1956). One of the key challenges 
that the DoH has historically faced is the irregularity of routine 
notifications, particularly from the private sector and public health 
facilities in non-endemic areas. In recent years, reporting appears to 
be gaining in efficiency, with an increase in malaria notifications from 
the non-endemic areas, especially Gauteng (Fig. 2). In this province, 
trends for malaria cases and related deaths show an increase over 
the past 2 years, with a peak in January. This seasonality is related 
to travellers returning from malaria-endemic areas, particularly 
Mozambique (Fig. 3).3
Malaria prevention and control strategies are being implemented 
robustly in the endemic provinces; however, similar strategies in 
the non-endemic provinces are lagging behind. This paper provides 
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Fig. 1. Malaria risk in South Africa. 
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Fig. 2. Malaria notifications for South Africa in 2010. Provinces: L – Lim-
popo; MP – Mpumalanga; KZN – KwaZulu-Natal; NW – North West; GP 
– Gauteng; NC – Northern Cape; EC – Eastern Cape; WC – Western Cape; 
FS – Free State.
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advice on the key measures for malaria prevention and management. 
Successful malaria treatment is dependent on a high index of 
suspicion for malaria in patients with acute febrile illness, and urgent 
treatment with effective medication. 
Prevention of malaria 
Travellers to malaria areas in southern Africa will be particularly 
vulnerable as the malaria risk season peaks in the coming months; 
therefore emphasis should be placed on prevention. Measures to 
avoid mosquito bites are the mainstay of malaria prevention and 
should be emphasised at all times. Whether or not appropriate 
chemoprophylaxis is warranted, should be determined by weighing 
up the risk of contracting malaria against the risk of adverse effects. 
Malaria risk is determined by travel location and accommodation, 
as well as season and length of stay. For example, the risk in built-up 
cities during the dry winter months is significantly less than that at a 
river-side campsite in summer. Malaria-transmitting mosquitoes feed 
at night; therefore people 
should ideally remain 
indoors from dusk until 
dawn, in rooms that have 
screens on the windows and 
doors. 
The only insect repellents 
that are recommended are 
those containing diethyl 
toluamide (DEET).4 Products 
containing 30% DEET 
should be used for adults 
and children older than 2 
months, as they give longer 
protection. They should, 
however, only be applied to 
exposed skin, particularly in 
young children. There is no 
benefit from using products 
containing more than 50% 
DEET.5
If the risk of contracting 
malaria warrants more protection 
than mosquito avoidance, 
chemoprophylaxis should be 
advised. There are 3 effective 
options available in South Africa; 
all require a doctor’s prescription; 
therefore travellers should prepare 
for their travel timeously:
•    Mefloquine (weekly): start at 
least 1 week before entering a 
malaria area, take weekly while 
there and for 4 weeks after 
leaving the malaria area
•    Doxycycline (daily): start 1 - 2 
days before entering a malaria 
area, take daily while there and 
for 4 weeks after exiting the 
malaria area
•    Atovaquone-proguanil (daily): 
start 1 - 2 days before entering 
the malaria area, take daily 
while there and for 7 days after 
leaving the area.1
All 3 medicines are effective if taken correctly and if compliance 
is assured.1 The chemoprophylaxis selection depends on the 
duration of visit, affordability, age, whether the person is pregnant 
or breastfeeding, has any medical conditions (e.g. epilepsy or 
depression), or is taking any other medication. Certain activities, 
such as flying or scuba diving, also need to be taken into account 
when choosing prophylaxis. The majority of adverse effects are mild; 
any severe adverse effects should be reported to the healthcare worker 
immediately, and the chemoprophylaxis changed if needed. 
There is no scientific evidence that natural or homoeopathic 
products are effective against malaria; therefore their use should be 
avoided in the prevention of this potentially life-threatening illness.6
Diagnosis and management of malaria
Successful malaria treatment is dependent on a high index of 
suspicion for malaria in patients with acute febrile illness, as well as 
urgent treatment with effective medicines. Plasmodium falciparum 
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Fig. 3. Malaria cases and deaths in Gauteng Province in 2010 and 2011.
Fig. 4. Clinical and laboratory features of uncomplicated and severe malaria.
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accounts for the majority of malaria cases in Southern Africa, 
and causes almost all severe and fatal instances of the disease. 
South Africans, including residents of seasonal malaria transmission 
areas, are non-immune and are consequently at increased risk for 
developing severe malaria.
The diagnosis and management of malaria is urgent; delayed 
diagnosis and inappropriate treatment are associated with significantly 
increased morbidity and mortality.7 Classically, malaria presents with 
fever, rigors, headache and myalgia (Fig. 4), but the clinical features 
are nonspecific and may be confused with many other diseases, 
especially influenza. A definitive diagnosis should be made promptly 
by detection of the parasite with microscopic examination of a blood 
smear, or with the use of a rapid malaria antigen test. An initial 
negative test does not exclude the diagnosis of malaria, and repeat 
testing is mandatory in patients with continued symptoms and no 
alternative definitive diagnosis. All patients with malaria require 
careful clinical and parasitological follow-up. 
For uncomplicated malaria, artemether-lumefantrine (Coartem) is 
recommended for first-line therapy. Alternatively, quinine plus either 
doxycycline or clindamycin can be used, if artemether-lumefantrine 
is unavailable or contra-indicated. High-level resistance precludes 
the use of chloroquine and sulfadoxine-pyrimethamine (SP) for P. 
falciparum malaria; halofantrine is not recommended.8 
The major complications of malaria include: cerebral malaria, 
hypoglycaemia, anaemia, renal failure, acute respiratory distress 
syndrome (ARDS) and metabolic acidosis (Fig. 4). These carry high 
mortality rates, especially in children, pregnant women and those 
with HIV/AIDS. These complications indicate the need for urgent 
hospital admission, and require specific management. 
For patients with severe malaria, intravenous artesunate is the 
preferred treatment; extensive studies in adults and children in 
Africa and Asia have shown that artesunate drastically reduces 
in-hospital mortality.9,10 Artesunate is not yet registered in South 
Africa, but is available in sentinel hospitals for the treatment of 
infected adults and children through the Parenteral Artesunate 
Access Programme. Where artesunate is not available, parenteral 
quinine is recommended, with an initial loading dose, and should be 
combined with doxycycline or clindamycin. 
Despite being a preventable and readily treatable disease, malaria 
continues to cause thousands of cases in South Africa each year, 
with a high risk of life-threatening disease, if diagnosis is delayed or 
ineffective treatment is given. 
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Key issues to note
Malaria is mainly transmitted from September to May in South 
Africa. Travellers should be informed about the preventive 
measures to be taken when travelling to endemic areas in and 
around the country. For more information, refer to the World 
Health Organization’s risk areas for malaria: http://www.who.int/
entity/ith/chapters/ith2011chap7.pdf. 11
Key malaria preventive measures:
•   avoidance of mosquito bites should form the basis of prevention 
•   effective chemoprophylaxis requires the most appropriate of 
the 3 recommended options for the individual concerned to be 
selected and to be taken correctly and for the full course; lack of 
adherence will lead to prophylactic failure.
Natural or homeopathic products should not be used for malaria 
prevention as they have not been shown scientifically to be 
effective.
Considerations for malaria diagnosis and management:
•   almost all South Africans (including residents of seasonal malaria 
transmission areas) are non-immune, and are consequently at 
increased risk for developing severe malaria
•   the diagnosis and management of malaria is urgent: delayed 
diagnosis and inappropriate treatment are associated with 
significantly increased morbidity and mortality
•   an initial negative test result does not exclude the diagnosis of 
malaria: repeat testing is mandatory in patients with continued 
symptoms and no alternative definitive diagnosis
•   a high index of suspicion for malaria in patients with acute 
febrile illness, and urgent treatment with an effective medicine, 
is crucial to successful treatment. 
Further guidance is available through National Guidelines for 
the Prevention/Treatment of Malaria (http://www.doh.gov.za/
docs/policy/2011/malaria_prevention.pdf and http://www.doh.
gov.za/docs/policy/2011/malaria_treatment.pdf), the Amayeza 
Information Centre (telephone: +27 (0)11 678 2332) and the UCT 
Medicines Information Centre (telephone: +27 (0)861 100 531).
